In last trading session, Aligos Therapeutics Inc (NASDAQ:ALGS) saw 0.37 million shares changing hands with its beta currently measuring 2.50. Company’s recent per share price
During the last session, Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares were 0.38 million, with the beta value of the company hitting 2.50. At the end
Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 2.65. At the close of
In last trading session, Aligos Therapeutics Inc (NASDAQ:ALGS) saw 0.47 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share price
During the last session, Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares were 0.32 million, with the beta value of the company hitting 2.70. At the end
Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 2.73. At the close of
In last trading session, Aligos Therapeutics Inc (NASDAQ:ALGS) saw 0.28 million shares changing hands with its beta currently measuring 2.55. Company’s recent per share price
During the last session, Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares were 0.43 million, with the beta value of the company hitting 2.39. At the end
In the last trading session, 1.52 million shares of the Aligos Therapeutics Inc (NASDAQ:ALGS) were traded, and its beta was 2.31. Most recently the company’s
In the last trading session, 3.13 million Aligos Therapeutics Inc (NASDAQ:ALGS) shares changed hands as the company’s beta touched 2.11. With the company’s per share
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
